Please login to the form below

Not currently logged in
Email:
Password:

QLT sells Acne drug to Allergan

QLT has entered into an agreement with Allergan for the sale of its worldwide rights to Aczone, a treatment gel for acne vulgaris
QLT has entered into an agreement with Allergan for the sale of its worldwide rights to Aczone, a treatment gel for acne vulgaris.

Under the terms of the agreement, QLT will receive a one-time payment of approximately $150m. Payment will be made upon closing of the deal, which is expected to take place in the Q3 2008.

Although licensed for treatment in the US and Canada over three years ago, Aczone was never marketed. QLT carried out further clinical trials after the FDA ordered a label restriction requiring blood screening before treatment. Earlier this year, the FDA removed the requirement for this restriction.

Bob Butchofsky, president and CEO of QLT said: "The divestment of Aczone is a major milestone for QLT and this transaction demonstrates that our persistence in completing the work needed to remove the blood monitoring restriction from the Aczone label in the United States provided significant value for our shareholders."

This is the second asset purchase agreement to divest non-core assets that the company has entered into since announcing its strategic restructuring earlier this year.

11th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics